Trial tests powerful drug duo against rare, aggressive kidney cancer
NCT ID NCT03274258
Summary
This study tested whether a combination of two immunotherapy drugs, nivolumab and ipilimumab, could help control a rare and aggressive type of kidney cancer called renal medullary carcinoma. It involved a small group of patients with advanced disease to see if the treatment could shrink their tumors and was safe. The trial was terminated early, meaning it stopped enrolling new participants before its planned completion.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.